ClinicalTrials.gg
CompletedNCT03076138Updated May 7, 2019

Gene-activated Bone Substitute for Maxillofacial Bone Regeneration

An interventional study of Gene-activated matrix (OCP + plasmid DNA with VEGF gene) in Bone Cysts, Bone Atrophy and Bone Deformity, sponsored by Histograft Co., Ltd.. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-05-07.

Sponsored by Histograft Co., Ltd. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of the gene-activated bone substitute consisting of octacalcium phosphate and plasmid DNA encoding vascular endothelial growth factor (VEGF) for maxillofacial bone regeneration. The patients with congenital and acquired maxillofacial bone defects and alveolar ridge atrophy will be enrolled.

Read the detailed description

All participants of the study will receive standard treatment according to the medical care standards for diseases and pathological conditions characterized by maxillofacial bone defects and/or alveolar ridge atrophy. Bone grafting procedures as part of the surgical treatment will be performed with the use of investigated medical device. The safety and efficacy of the implanted gene-activated bone substitute will be evaluated by clinical examination, comprehensive laboratory tests, and computer tomography within 6 months after surgery.

02

Conditions studied

  • Bone Cysts
  • Bone Atrophy
  • Bone Deformity
  • Bone Fracture
  • Bone Loss
  • Tooth Loss

Keywords

  • Gene-activated matrix
  • Bone substitute
  • Bone grafting
  • Dental implantation
  • gene therapy
  • plasmid DNA
  • VEGF gene
  • octacalcium phosphate
03

In context

Bone Cysts

18 studies on the registry are indexed under Bone Cysts; 5 are open to participants now.

This study's enrollment of 20 is above the median of 17 across 10 interventional studies indexed under Bone Cysts.

Browse Bone Cysts studies →

Lead sponsor

Histograft Co., Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained voluntary for participation in the clinical study;
  • congenital and acquired maxillofacial bone defects (sockets of extracted teeth, bone defects after injuries, surgeries, removal of benign neoplasms and pseudotumors, etc.) or alveolar ridge atrophy.

Exclusion criteria

Exclusion Criteria:

  • not able or unwilling to give voluntary for the study or follow requirements of the clinical study;
  • decompensated chronic visceral diseases;
  • laboratory abnormalities;
  • , and antibodies in serum;
  • alcohol consumption within 4 days prior the study;
  • history of drug addiction;
  • participation in other clinical trials (or administration of study products) within 3 months prior the study;
  • conditions limiting study compliance (dementia, psycho-neurological diseases, drug addiction, alcoholism, etc.);
  • pregnancy or lactation;
  • including post-treatment period (surgical, chemotherapy, radiation therapy both alone and in different combinations) less than 5 years prior the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Test group

    Bone grafting with gene-activated matrix (OCP + plasmid DNA with VEGF gene)

    Device: Gene-activated matrix (OCP + plasmid DNA with VEGF gene)

Interventions

  • DeviceGene-activated matrix (OCP + plasmid DNA with VEGF gene)

    Bone grafting procedure with investigated medical device

06

What researchers measure

Primary outcomes

  1. Bone tissue formation in the field of gene-activated bone substitute implantation

    To determine the quantity of newly formed bone tissue the following morphometric parameters will be measured on CT scan using special tools ("ROI", region of interest, etc.): * average density (in HU); * size (length, width, height) and volume. All together both measurements allow to determine "bone tissue formation" as a value derived from the presence of newly formed bone tissue and its volume correspondence with the quantity of the material implanted.

    Time frame: 6 months

Secondary outcomes

  1. Adverse Events and Serious Adverse Events

    Evaluation of the Adverse Events and Serious Adverse Events frequency

    Time frame: 6 months

  2. Surgical failure rate

    Evaluation of the events frequency when the surgery was not completed due to the reasons related with gene-activated bone substitute

    Time frame: 6 months

07

Study locations

1 site
  • A.I. Moscow State University of Medicine and Dentistry
    Moscow, 127473, Russian Federation
08

References and documents

Publications

  • Deev RV, Drobyshev AY, Bozo IY, Isaev AA. Ordinary and Activated Bone Grafts: Applied Classification and the Main Features. Biomed Res Int. 2015;2015:365050. doi: 10.1155/2015/365050. Epub 2015 Nov 15. PubMed 26649300 ↗
  • Komlev VS, Barinov SM, Bozo II, Deev RV, Eremin II, Fedotov AY, Gurin AN, Khromova NV, Kopnin PB, Kuvshinova EA, Mamonov VE, Rybko VA, Sergeeva NS, Teterina AY, Zorin VL. Bioceramics composed of octacalcium phosphate demonstrate enhanced biological behavior. ACS Appl Mater Interfaces. 2014 Oct 8;6(19):16610-20. doi: 10.1021/am502583p. Epub 2014 Sep 16. PubMed 25184694 ↗
  • Komlev VS, Popov VK, Mironov AV, Fedotov AY, Teterina AY, Smirnov IV, Bozo IY, Rybko VA, Deev RV. 3D Printing of Octacalcium Phosphate Bone Substitutes. Front Bioeng Biotechnol. 2015 Jun 8;3:81. doi: 10.3389/fbioe.2015.00081. eCollection 2015. PubMed 26106596 ↗
  • Deev R, Plaksa I, Bozo I, Isaev A. Results of an International Postmarketing Surveillance Study of pl-VEGF165 Safety and Efficacy in 210 Patients with Peripheral Arterial Disease. Am J Cardiovasc Drugs. 2017 Jun;17(3):235-242. doi: 10.1007/s40256-016-0210-3. PubMed 28050885 ↗
  • Deev RV, Bozo IY, Mzhavanadze ND, Voronov DA, Gavrilenko AV, Chervyakov YV, Staroverov IN, Kalinin RE, Shvalb PG, Isaev AA. pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia. J Cardiovasc Pharmacol Ther. 2015 Sep;20(5):473-82. doi: 10.1177/1074248415574336. Epub 2015 Mar 13. PubMed 25770117 ↗

Individual participant data

Plan to share: Yes — Detailed results of the study will be published in a specialized peer-reviewed scientific journal with an open access

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Dec 2018, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2017
First posted
Mar 10, 2017
StartActual
Mar 6, 2017
Primary completionActual
Dec 14, 2018
CompletionActual
Dec 14, 2018
Last update
May 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03076138
Lead sponsor
Histograft Co., Ltd.
Collaborators
Moscow State University of Medicine and Dentistry
Responsible party
Sponsor
First posted
Mar 10, 2017
Start date
Mar 6, 2017
Primary completion
Dec 14, 2018
Completion
Dec 14, 2018
Last update
May 7, 2019

Study contacts

Alexey Y. Drobyshev, MD,PhD,Prof.
principal investigator · A.I. Evdokimov Moscow State University of Medicine and Dentistry

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion